BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 28084679)

  • 1. Impacts of donor-specific anti-HLA antibodies and antibody-mediated rejection on outcomes after intestinal transplantation in children.
    Petit LM; Rabant M; Canioni D; Suberbielle-Boissel C; Goulet O; Chardot C; Lacaille F
    Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 28084679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
    Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
    Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
    Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute antibody-mediated rejection in ABO-compatible pediatric liver transplant recipients: case series and review of the literature.
    Wozniak LJ; Naini BV; Hickey MJ; Bhattacharyya S; Reed EF; Busuttil RW; Farmer DG; Vargas JH; Venick RS; McDiarmid SV
    Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27597379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Monitoring of Donor-specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies.
    Kubal C; Mangus R; Saxena R; Lobashevsky A; Higgins N; Fridell J; Tector AJ
    Transplantation; 2015 Aug; 99(8):e49-56. PubMed ID: 25769071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation.
    Gerlach UA; Lachmann N; Sawitzki B; Arsenic R; Neuhaus P; Schoenemann C; Pascher A
    Transpl Int; 2014 Mar; 27(3):280-9. PubMed ID: 24279605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
    Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW
    Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work?
    Vacha M; Chery G; Hulbert A; Byrns J; Benedetti C; Finlen Copeland CA; Gray A; Onwuemene O; Palmer SM; Snyder LD
    Clin Transplant; 2017 Mar; 31(3):. PubMed ID: 27988971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
    Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
    Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
    Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
    Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
    Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
    Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of antibodies in kidney transplant].
    Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
    G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
    Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Milongo D; Suc B; Duffas JP; Alric L; Bureau C; Guilbeau-Frugier C; Rostaing L; Kamar N
    Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies.
    Alvarez-Márquez A; Aguilera I; Gentil MA; Caro JL; Bernal G; Fernández Alonso J; Acevedo MJ; Cabello V; Wichmann I; Gonzalez-Escribano MF; Núñez-Roldán A
    Transplantation; 2009 Jan; 87(1):94-9. PubMed ID: 19136897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-mediated rejection in ABO compatible husband to wife living donor liver transplant and review of the literature.
    Kheradmand T; Anthony TL; Harland RC; Testa G; Hart J; Renz J; Te HS; Marino SR
    Hum Immunol; 2014 Jun; 75(6):578-83. PubMed ID: 24530823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of complement component 4d immunohistochemistry to ABO-compatible and ABO-incompatible liver transplantation.
    Salah A; Fujimoto M; Yoshizawa A; Yurugi K; Miyagawa-Hayashino A; Sumiyoshi S; Minamiguchi S; Uemoto S; Maekawa T; Haga H
    Liver Transpl; 2014 Feb; 20(2):200-9. PubMed ID: 24470446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
    Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
    Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Complement-binding Donor-specific Antibodies, Not IgG-antibody Strength Nor C4d Status, at Antibody-mediated Rejection Diagnosis Is an Independent Predictor of Kidney Graft Failure.
    Malheiro J; Santos S; Tafulo S; Dias L; Martins S; Fonseca I; Almeida M; Pedroso S; Beirão I; Castro-Henriques A; Cabrita A
    Transplantation; 2018 Nov; 102(11):1943-1954. PubMed ID: 29757900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study.
    Slatinska J; Slavcev A; Honsova E; Hruba P; Kratochvilova I; Rohal T; Viklicky O
    HLA; 2018 Dec; 92 Suppl 2():47-50. PubMed ID: 30168284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.